Acute Monoblastic Leukemia (AmoL)
Symptoms, Doctors, Treatments, Advances & More

Acute Monoblastic Leukemia (AmoL) Overview

Save information for later
Sign Up

Learn About Acute Monoblastic Leukemia (AmoL)

View Main Condition: Leukemia

What is the definition of Acute Monoblastic Leukemia (AmoL)?
Acute monoblastic leukemia (AML-M5), is one of the most common subtypes of acute myeloid leukemia (AML; see this term) that is either comprised of more than 80% of monoblasts (AML-M5a) or 30-80% monoblasts with (pro)monocytic differentiation (AML-M5b). AML-M5 presents with asthenia, pallor, fever, and dizziness. Specific features of AML-M5 include hyperleukocytosis, propensity for extramedullary infiltrates, coagulation abnormalities including disseminated intravascular coagulation and neurological disorders. Leukemia cutis and gingival infiltration can also be seen. A characteristic translocation observed in AML-M5 is t(9;11).
What are the alternative names for Acute Monoblastic Leukemia (AmoL)?
  • Acute monoblastic leukemia
  • AML M5
  • AML-M5
  • Acute monocytic leukemia
  • Acute myeloblastic leukemia type 5
Who are the top Acute Monoblastic Leukemia (AmoL) Local Doctors?
Marina Konopleva
Elite in Acute Monoblastic Leukemia (AmoL)
Dr. Marina Konopleva
Hematology
Elite in Acute Monoblastic Leukemia (AmoL)
Dr. Marina Konopleva
Hematology

Montefiore Medical Center

111 East 210th Street, 
Bronx, NY 
718-920-4321
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Marina Konopleva, MD, Phd, is Professor, Oncology, Professor, Molecular Pharmacology, Director, Leukemia Program and Co-Director, Blood Cancer Institute, at Montefiore Einstein. Her clinic focus centers on treating patients with hematologic malignancies, with an emphasis on acute myeloid and acute lymphoblastic leukemia. She has additional expertise in treating patients with high-risk myelodysplastic syndrome and chronic myeloid leukemia. Dr. Konopleva is rated as an Elite provider by MediFind in the treatment of Acute Monoblastic Leukemia (AmoL). Her top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Myelodysplastic Syndrome (MDS), Bone Marrow Aspiration, and Bone Marrow Transplant.

Daniel Pollyea
Elite in Acute Monoblastic Leukemia (AmoL)
Dr. Daniel Pollyea
Hematology
Elite in Acute Monoblastic Leukemia (AmoL)
Dr. Daniel Pollyea
Hematology

University Of Colorado Hospital

12605 E 16th Ave, 
Aurora, CO 
720-777-1234
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Daniel Pollyea is a Hematologist in Aurora, Colorado. Dr. Pollyea is rated as an Elite provider by MediFind in the treatment of Acute Monoblastic Leukemia (AmoL). His top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Acute Monoblastic Leukemia (AmoL), Bone Marrow Aspiration, and Bone Marrow Transplant.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Acute Monoblastic Leukemia (AmoL)
Wanggang T. Zhang
Elite in Acute Monoblastic Leukemia (AmoL)
Wanggang T. Zhang
157 Xiwu Road, 
Xi'an, CN 

Wanggang Zhang practices in Xi'an, China. Zhang is rated as an Elite expert by MediFind in the treatment of Acute Monoblastic Leukemia (AmoL). Their top areas of expertise are Acute Monoblastic Leukemia (AmoL), Acute Myeloid Leukemia (AML), Leukemia, and Multiple Myeloma.

View All Doctors
What are the latest Acute Monoblastic Leukemia (AmoL) Clinical Trials?
A Phase 1, Open-Label, Dose Escalation and Expansion Study of STX-0712 in Patients With Advanced Hematologic Malignancies
A Phase 1, Open-Label, Dose Escalation and Expansion Study of STX-0712 in Patients With Advanced Hematologic Malignancies
Enrollment Status: Recruiting
Publish Date: February 09, 2026
Intervention Type: Biological
Study Phase: Phase 1

Summary: This is a first-in-human, multicenter, open-label, phase 1 study to evaluate the safety, PK, PD and preliminary efficacy of STX-0712 in patients with advanced CMML and AML for whom there are no further treatment options known to confer clinical benefit.

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Multicenter, Randomized, Controlled Clinical Trial of Venetoclax, Azacytidine Combined With Chidamide for the Treatment of Newly Diagnosed Acute Monocytic Leukemia Patients That Are Ineligible for Intensive Chemotherapy
A Multicenter, Randomized, Controlled Clinical Trial of Venetoclax, Azacytidine Combined With Chidamide for the Treatment of Newly Diagnosed Acute Monocytic Leukemia Patients That Are Ineligible for Intensive Chemotherapy
Enrollment Status: Recruiting
Publish Date: November 21, 2025
Intervention Type: Drug
Study Phase: Phase 2

Summary: This study is to investigate the therapeutic efficacy and side effect of venetoclax, azacytidine combined with chidamide for newly diagnosed acute monocytic leukemia patients that are ineligible for intensive chemotherapy

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center